Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

Learn more about whether Pegasystems Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Learn more about whether LiveRamp Holdings, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

This analysis examines Vertex's strengths ... Is the current valuation too rich given pipeline uncertainties? Vertex's stock has enjoyed a premium valuation, trading at approximately 27 times ...

According to InvestingPro analysis, the company stands as a prominent player in the Biotechnology industry ... This readout is viewed as a significant potential catalyst for Vertex's stock, as success ...